Valuation: VolitionRx Limited

Market Cap 2.56M 2.27M 2.11M 1.92M 3.62M 243M 3.68M 25.33M 9.93M 127M 9.6M 9.4M 404M P/E 2026 *
-0.09x
P/E 2027 * -0.18x
Enterprise Value 2.56M 2.27M 2.11M 1.92M 3.62M 243M 3.68M 25.33M 9.93M 127M 9.6M 9.4M 404M EV / Sales 2026 *
0.94x
EV / Sales 2027 * 0.28x
Free-Float
94.07%
Yield 2026 *
-
Yield 2027 * -
1 day-4.46%
1 week-14.77%
Current month-30.19%
1 month-34.49%
3 months-84.47%
6 months-94.89%
Current year-96.48%
1 week 0.17
Extreme 0.1748
0.22
1 month 0.17
Extreme 0.1748
0.28
Current year 0.17
Extreme 0.1748
7.73
1 year 0.17
Extreme 0.1748
9.6
3 years 0.17
Extreme 0.1748
24.6
5 years 0.17
Extreme 0.1748
82.8
10 years 0.17
Extreme 0.1748
136.8
Manager TitleAgeSince
Chief Executive Officer 55 2011-10-05
Director of Finance/CFO 56 2021-01-31
Chief Tech/Sci/R&D Officer 49 2024-03-31
Director TitleAgeSince
Director/Board Member 55 2011-10-05
Director/Board Member 77 2011-10-05
Director/Board Member 64 2019-10-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/28/26 Tax

Executive/Senior Manager

-284 0.0010%
9/28/26 Tax

Chief Operating Officer

-608 0.0022% -
3/17/26
Concord International, Inc.
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
-4.46%-14.77%-97.99%-98.64% 2.68M
-6.60%-8.56%+42.79%+64.16% 68.98B
-4.09%-0.11%+2.31%+54.81% 53.15B
+0.03%+5.56%+10.18%+41.75% 50.83B
-1.53%+2.70%+29.72%+34.13% 44.61B
-1.34%+4.12%+16.05%+112.18% 42.53B
-5.97%-6.22%+258.21%+421.57% 40.57B
+6.53%+8.02%+15.74%+53.94% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
-2.76%-9.54%-16.53%-9.55% 22.66B
Average -2.11%-1.75%+29.20%+67.27% 37.97B
Weighted average by Cap. -2.43%-0.10%+44.74%+90.24%

Financials

2026 *2027 *
Net sales 2.72M 2.42M 2.24M 2.04M 3.85M 258M 3.91M 26.97M 10.58M 135M 10.22M 10M 430M 9.27M 8.24M 7.64M 6.95M 13.12M 880M 13.33M 91.85M 36.01M 459M 34.81M 34.07M 1.46B
Net income -22.25M -19.78M -18.33M -16.68M -31.47M -2.11B -31.98M -220M -86.4M -1.1B -83.51M -81.73M -3.51B -18.42M -16.37M -15.18M -13.81M -26.05M -1.75B -26.47M -182M -71.52M -912M -69.13M -67.65M -2.91B
Net Debt - -
Projected Income Statement - Annual - VolitionRx Limited
Logo VolitionRx Limited
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
26-10-16 US$0.1801 -4.46% 475,998
26-10-15 US$0.1885 +5.31% 1,431,854
26-10-14 US$0.1790 -3.09% 993,183
26-10-13 US$0.1847 -9.06% 1,844,149
26-10-12 US$0.2031 -3.88% 777,557
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - VolitionRx Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.1801USD
Average target price
13.62USD
Spread / Average Target
+7,463.58%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - VolitionRx Limited
  1. Stock Market
  2. Stocks
  3. VNRX Stock